The Latin America, Middle East and Africa Microbiome Diagnostics Market would witness market growth of 21.2% CAGR during the forecast period (2023-2030).
The Brazil market dominated the LAMEA Microbiome Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $7,003.2 Thousands by 2030. The Argentina market is experiencing a CAGR of 21.9% during (2023 - 2030). Additionally, The UAE market would exhibit a CAGR of 20.8% during (2023 - 2030).
It has applications in women’s health, particularly in understanding the vaginal microbiota and its implications for reproductive health and gynecological conditions. Perturbations in the vaginal microbiome are associated with conditions such as bacterial vaginosis, urinary tract infections, and preterm birth. It enables the characterization of the vaginal microbiome and identification of microbial biomarkers predictive of adverse outcomes, guiding personalized interventions and preventive measures.
Also, chronic diseases such as diabetes, cancer, inflammatory bowel diseases (IBD), and asthma are associated with alterations in the microbiome composition. For example, according to Statistics Canada, in 2021, 45.1% of Canadians had at least one serious chronic illness. In 2021, around 2.5 million Canadians reported having unmet healthcare needs. Similarly, according to Eurostat, in 2022, over one-third (36.1%) of EU citizens stated that they had a long-standing (chronic) health issue. As the prevalence of these chronic conditions rises, there is a growing demand for microbiome diagnostics to assess microbial imbalances, identify disease biomarkers, and personalize treatment approaches.
The expansion of the healthcare sector in Saudi Arabia will likely drive demand for microbiome diagnostics as clinicians seek to integrate these innovative tools into diagnostic workflows to improve patient outcomes. According to the International Trade Administration (ITA), Saudi Arabia contributes 60% of the healthcare expenditures of the Gulf Cooperation Council (GCC) nations, and the Saudi Arabian government continues to prioritize this sector. The nation spent $50.4 billion on healthcare and social development in 2023, representing 16.96 percent of its budget and ranking second only to education in terms of expenditure. Thus, the rising healthcare sector and growing proportion of elderly in the region drive the market’s growth.
Based on Application, the market is segmented into Disease Diagnostics (Gastrointestinal Disorders, Metabolic Diseases and Others) and Research Application. Based on Product, the market is segmented into Reagents & Kits and Instruments. Based on Sample, the market is segmented into Fecal, Saliva, Skin, and Others. Based on Technology, the market is segmented into 16S rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics and Others. Based on End User, the market is segmented into Hospitals, Academic & Research Institutes, and Biotechnology & Pharmaceutical Companies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Brazil market dominated the LAMEA Microbiome Diagnostics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $7,003.2 Thousands by 2030. The Argentina market is experiencing a CAGR of 21.9% during (2023 - 2030). Additionally, The UAE market would exhibit a CAGR of 20.8% during (2023 - 2030).
It has applications in women’s health, particularly in understanding the vaginal microbiota and its implications for reproductive health and gynecological conditions. Perturbations in the vaginal microbiome are associated with conditions such as bacterial vaginosis, urinary tract infections, and preterm birth. It enables the characterization of the vaginal microbiome and identification of microbial biomarkers predictive of adverse outcomes, guiding personalized interventions and preventive measures.
Also, chronic diseases such as diabetes, cancer, inflammatory bowel diseases (IBD), and asthma are associated with alterations in the microbiome composition. For example, according to Statistics Canada, in 2021, 45.1% of Canadians had at least one serious chronic illness. In 2021, around 2.5 million Canadians reported having unmet healthcare needs. Similarly, according to Eurostat, in 2022, over one-third (36.1%) of EU citizens stated that they had a long-standing (chronic) health issue. As the prevalence of these chronic conditions rises, there is a growing demand for microbiome diagnostics to assess microbial imbalances, identify disease biomarkers, and personalize treatment approaches.
The expansion of the healthcare sector in Saudi Arabia will likely drive demand for microbiome diagnostics as clinicians seek to integrate these innovative tools into diagnostic workflows to improve patient outcomes. According to the International Trade Administration (ITA), Saudi Arabia contributes 60% of the healthcare expenditures of the Gulf Cooperation Council (GCC) nations, and the Saudi Arabian government continues to prioritize this sector. The nation spent $50.4 billion on healthcare and social development in 2023, representing 16.96 percent of its budget and ranking second only to education in terms of expenditure. Thus, the rising healthcare sector and growing proportion of elderly in the region drive the market’s growth.
Based on Application, the market is segmented into Disease Diagnostics (Gastrointestinal Disorders, Metabolic Diseases and Others) and Research Application. Based on Product, the market is segmented into Reagents & Kits and Instruments. Based on Sample, the market is segmented into Fecal, Saliva, Skin, and Others. Based on Technology, the market is segmented into 16S rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics and Others. Based on End User, the market is segmented into Hospitals, Academic & Research Institutes, and Biotechnology & Pharmaceutical Companies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- Illumina, Inc.
- Becton, Dickinson and Company
- Genetic Analysis AS
- Microba Life Sciences Limited
- BioMe Oxford Ltd
- Viome Life Sciences, Inc.
- GoodGut S.L.U. (HIPRA, S.A.)
- Sun Genomics
- Origin Sciences Limited
- Decode Age
Market Report Segmentation
By Application- Disease Diagnostics
- Gastrointestinal Disorders
- Metabolic Diseases
- Others
- Research Application
- Reagents & Kits
- Instruments
- Fecal
- Saliva
- Skin
- Others
- 16S rRNA Sequencing
- Shot Gun Metagenomics
- Metatranscriptomics
- Others
- Hospitals
- Academic & Research Institutes
- Biotechnology & Pharmaceutical Companies
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. LAMEA Microbiome Diagnostics Market by Application
Chapter 6. LAMEA Microbiome Diagnostics Market by Product
Chapter 7. LAMEA Microbiome Diagnostics Market by Sample
Chapter 8. LAMEA Microbiome Diagnostics Market by Technology
Chapter 9. LAMEA Microbiome Diagnostics Market by End User
Chapter 10. LAMEA Microbiome Diagnostics Market by Country
Chapter 11. Company Profiles
Companies Mentioned
- Illumina, Inc.
- Becton, Dickinson and Company
- Genetic Analysis AS
- Microba Life Sciences Limited
- BioMe Oxford Ltd
- Viome Life Sciences, Inc.
- GoodGut S.L.U. (HIPRA, S.A.)
- Sun Genomics
- Origin Sciences Limited
- Decode Age
Methodology
LOADING...
